

Research & Reviews: Journal of Nursing & Health Sciences

Schizophrenia: A General Review

Nishikant Doble*

Shrimati Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur MH INDIA

Review Article

Received date: 23/08/2016

Accepted date: 24/08/2016

Published date: 31/08/2016

*For Correspondence

Nishikant Doble, Division of Neuroscience,
Department of Pharmacology, Shrimati Kishoritai
Bhoyar College of Pharmacy, Kamptee, Nagpur,
India, Tel: 9960228657.

E-mail: nishikantdoble@gmail.com

Keywords: Schizophrenia, Symptoms,
Pharmacological and non-pharmacological
treatment.

ABSTRACT

Schizophrenia is a chronic and severe mental disorder that affects person's thoughts, feelings, and behaviour. People with schizophrenia seem like they have lost contact with reality. Although schizophrenia is less common as other mental illnesses, the symptoms can be extremely disabling.

INTRODUCTION

Schizophrenia, a weakening mental sickness, has proportionate prevalence among men and ladies of the world's one per cent population ^[1]. World Health Organization defines schizophrenia as a severe mental disorder, characterized by disrupted thinking, affecting perception, and language. It often includes psychotic experiences, such as hearing voices or delusions ^[2]. Schizophrenia is a multifaceted issue including a mind boggling collaboration of mental and organic variables to subvert working over the span of the disease ^[3].

HISTORY

Haslam initially perceived schizophrenia in his book, "Observations on Madness and Melancholy" and called it as type of madness. In 1898, a German psychiatrist, Emil Kraepelin, portrayed the confusion more with the side effects named under the Latin expression, dementia praecox. Later, Bleuler, a Swiss psychiatrist and eugenicist, initially presented the expression "Schizophrenia" in 1908. Schizophrenia originates from the mix of the Greek words for split (skhizein) and brain (phren). As per Blueuler, all the abnormal practices appeared by individuals with this issue were an acquainted part of the fundamental elements of identity.

SYMPTOMS OF SCHIZOPHRENIA

According to Mueser and Gingerich it is like imagining when one is wide alert. While we dream, we trust that it is genuine and not creative ability. In any case, when we wake up, we would realize that it was just our creative ability and in this way it would more often than not influence us ^[4]. Be that as it may, a schizophrenic has trouble recognizing reality and deception notwithstanding when wakeful. Not at all like despondency that incorporates pity, alarm issue joined by extreme sentiments of nervousness, schizophrenia is gathering of side effects that are not as a matter of course found in every one of the general population who are schizophrenic ^[5]. Side effects are diverse for every situation. Inside such complexities, analysts have recognized gathering of side effects that make up the turmoil. These groups of side effects are called positive indications, negative manifestations and cognitive symptoms ^[6].

POSITIVE SYMPTOMS

Positive symptoms can be easily identified and can be classified as psychotic behaviours not seen in healthy people. Such symptoms include hallucinations, delusions, and abnormal motor behaviour in varying degrees of severity ^[7].

NEGATIVE SYMPTOMS

Negative symptoms are rather difficult to diagnose and are associated with high morbidity because they disturb the patient's emotions and behaviour ^[8]. The most common negative symptoms are avolition (inability to initiate and persist in activities), alogia (relative absence of Speech), anhedonia (lack of pleasure) and diminished emotional expression ^[9]. Negative symptoms may be either primary to a diagnosis of schizophrenia or secondary to medication, or environmental factor a concomitant psychotic diagnosis ^[10].

COGNITIVE SYMPTOMS

Cognitive symptoms, being the newest classification are nonspecific. These include disorganized thought, speech and/or attention, ultimately impairing the individual's communication ability ^[11].

Substance-abuse disorders occur commonly among these patients; these disorders generally include tobacco, alcohol, and prescription medications ^[12].

DIAGNOSIS

As portrayed before, schizophrenia is an incessant issue with various side effects, where no single manifestation is pathogenic ^[13]. An analysis of schizophrenia is come to through an appraisal of patient-particular signs and indications, as depicted in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The DSM-5 expresses that the demonstrative criteria [for schizophrenia] incorporate the tirelessness of two or a greater amount of the accompanying dynamic stage side effects, each going on for a huge bit of no less than a one-month time span: daydreams, mind flights, disrupted discourse, horribly scattered or mental conduct, and negative symptoms. At slightest one of the qualifying manifestations must be fancies, pipedreams, or confused speech ^[14,15].

In addition, the DSM-5 expresses that, to warrant a conclusion of schizophrenia, the patient should likewise display a diminished level of working with respect to work, interpersonal connections, or self-care. There must likewise be nonstop indications of schizophrenia for no less than six months, including the one-month time of dynamic stage side effects noted above ^[16-18].

A complete differential determination of schizophrenia is important to recognize the confusion from other mental conditions, for example, real depressive issue with insane or mental components; schizoaffective turmoil; schizophreniform jumble; fanatical habitual issue; body dysmorphic confusion; and post-traumatic anxiety issue. Schizophrenia can be separated from these comparable conditions through a cautious examination of the span of the sickness, the planning of daydreams or mental trips, and the seriousness of depressive or hyper symptoms ^[19-21]. Also, the clinician must affirm that the exhibiting manifestations are not a consequence of substance misuse or another restorative condition ^[22].

AETIOLOGY

One clarification for the improvement of schizophrenia is that the turmoil starts in utero. Obstetric entanglements, including seeping amid pregnancy, gestational diabetes, crisis cesarean segment, asphyxia, and low birth weight, have been connected with schizophrenia later in life ^[23-25]. Fetal unsettling influences amid the second trimester—a key stage in fetal neurodevelopment—have been specifically noteworthy to researchers. Infections and overabundance stress levels amid this period have been connected to a multiplying of the danger of posterity creating schizophrenia ^[26,27].

Environmental and social factors may also play a role in the development of schizophrenia, especially in persons who are vulnerable to the disorder ^[28-31]. Environmental stressors linked to schizophrenia include minority ethnicity, childhood trauma, residence in an urban area, and social isolation ^[32-39]. In addition, social stressors, such as discrimination or poverty, may predispose individuals toward delusional or paranoid thinking ^[40-45].

Logical confirmation bolsters hereditary elements assume an imperative part in the causation of schizophrenia; concentrates on have demonstrated that the danger of ailment is around 10% for a first-degree relative and 3% for a brief moment degree relative ^[46-50]. For the situation of monozygotic twins, the danger of one twin having schizophrenia is 48% if alternate has the turmoil, while the danger is 12% to 14% in dizygotic twins ^[51-55]. If both guardians have schizophrenia, the danger that they will deliver a tyke with schizophrenia is roughly 40% ^[55-60].

TREATMENT OPTIONS

Nonpharmacological therapy

The objectives in treating schizophrenia incorporate focusing on side effects, anticipating backslide, and expanding versatile

working so that the patient can be coordinated once again into the community. Since patients once in a while come back to their standard level of versatile working, both nonpharmacological and pharmacological medications must be utilized to enhance long haul outcomes. Pharmacotherapy is the backbone of schizophrenia administration, however remaining indications may hold on [61-65]. Hence, non-pharmacological medicines, such as psychotherapy, are likewise important.

Not just do non-pharmacological treatments fill in crevices in pharmacological medicines; they can guarantee that patients stay disciplined to their medications [66-70]. Non-adherence rates in schizophrenia range from 37% to 74%, contingent upon the report [71]. Individuals with mental issues have a tendency to be less compliant for a few reasons [72]. They may deny their disease; they may encounter unfavourable impacts that prevent them from taking more medicine; they may not see their requirement for prescription; or they may have bombastic indications or paranoia [73].

PHARMACOLOGICAL THERAPY

As indicated by the American Psychiatric Association, second-generation (atypical) antipsychotics (SGAs) - except for clozapine—are the operators of decision for first-line treatment of schizophrenia. Clozapine is not suggested in light of its danger of agranulocytosis [74]. SGAs are normally favoured over original (typical) antipsychotics (FGAs) in light of the fact that they are connected with less extrapyramidal symptoms [75]. However, SGAs have a tendency to have metabolic reactions, for example, weight addition, hyperlipidaemia and diabetes mellitus. These antagonistic impacts can add to the expanded danger of cardiovascular mortality seen in schizophrenia patients [76].

Mix treatment is prescribed just in the later phases of the treatment algorithm [77]. The normal solution of two or more antipsychotics is not suggested in light of the fact that it might build the danger of medication connections, non-adherence, and prescription errors [78].

Before another antipsychotic specialist is started, the patient's finished medicine history ought to be acquired [79]. Whether the patient has demonstrated a great or unfavourable reaction to past antipsychotic treatment will control the determination of another medication [80-85].

CONCLUSION

Schizophrenia is a severe disabling disease that requires brief treatment at the principal indications of a maniacal scene [86-90]. Clinicians must consider treatment-related unfriendly impacts and the potential for non-adherence when building up a far-reaching treatment arrangement. In spite of the fact that patients can increment versatile working through accessible pharmacological and nonpharmacological treatment options, it is trusted that future exploration will address crevices in treatment and conceivably a cure for schizophrenia [91-100].

REFERENCES

1. E, et al. Epidemiology of schizophrenia: Review of findings and myths. *Psychiatr Clin North Am.* 2007;30:323-338.
2. Allebeck P. Schizophrenia: A life-shortening disease. *Schizophr Bull.* 1989;15:81-89.
3. Palmer BA, et al. The lifetime risk of suicide in schizophrenia - a reexamination. *Arch Gen Psychiatry.* 2005;62:247-253.
4. Mueser KT, et al. Educational family therapy for schizophrenia: A new treatment model for clinical service and research. *Schizophr Res.* 1994;13:99-107.
5. Allardyce J and Boydell J. Environment and schizophrenia: Review: The wider social environment and schizophrenia. *Schizophr Bull.* 2006;32:592-598.
6. Henry JD, et al. Clinical assessment of social cognitive function in neurological disorders. *Nat Rev Neurol.* 2016;12:28-39.
7. Grover S, et al. Religion, spirituality and schizophrenia: A review. *Indian J Psychol Med.* 2014;36:119-124.
8. Kaiser S, et al. Individual negative symptoms and domains - Relevance for assessment, pathomechanisms and treatment. *Schizophr Res.* 2016;S0920-9964:30329-2.
9. Tandon R, et al. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. *Schizophr Res.* 2009;110:1-23.
10. Szöke A, et al. Longitudinal studies of cognition in schizophrenia: Meta-analysis. *Br J Psychiatry.* 2008;192:248-257.
11. Polo-López R, et al. Outcome of cognitive-behavioral therapy for relatives of people with severe mental disorders. *Psicothema.* 2016;28:227-234.
12. Singh S and Balhara YPS. A Review of Indian research on co-occurring psychiatric disorders and alcohol use disorders. *Indian J Psychol Med.* 2016;38:10-19.
13. Kay SR, et al. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull.* 1987;13:261-276.
14. Cornblatt BA, et al. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. *Psychiatry Res.* 1989;29:65-85.

15. Ávila CC, et al. Functioning and disability in bipolar disorders: A systematic review of literature using the ICF as a reference. *Bipolar Disord.* 2010;12:473-482.
16. Tsuneoka T, et al. The effect of multi-disciplinary psycho-education for hospitalized schizophrenia patients: The key factors for re-hospitalization. *Brain Disord Ther.* 2015;4:181.
17. Pino MC, et al. Effect of gaze direction on orienting of attention in patients with schizophrenia: Attention or social cognition deficit? *J Depress Anxiety.* 2015;4:200.
18. Hernandez-Yáñez HD, et al. Family support and adherence to treatment in patients diagnosed with schizophrenia in tabasco, Mexico: A case- series study. *J Psychiatry.* 2015;18:304.
19. Inanaga K. Recovery from schizophrenia with bioactive substances in *Heridium erinaceum*. *Int J Sch Cog Psychol.* 2015;S1:003.
20. Tao J, et al. Effects of cognitive rehabilitation training on schizophrenia: 2 years of follow-up. *J Psychiatry.* 2015;S1:006.
21. Kamal SM and Dine SE. Neuroplasticity and antipsychotics in treatment of schizophrenia. *J Neurol Disord.* 2015;3:232.
22. Fandiño-Franky J. Neuroplasticity and antipsychotics in treatment of schizophrenia. *J Neurol Disord.* 2015;3:e115.
23. Elsayed MA. Schizophrenia in Hollywood movies. *J Mass Communicat Journalism.* 2015;5:256.
24. Suresh Kumar PN and George B. Life events, social support, coping strategies and quality of life in attempted suicide: A case-control study. *Indian J Psychiatry.* 2013;55:46-51.
25. Kamal MS and El Dine S. Spotlights on pharmacogenetics of schizophrenia and depressed mood. *Gene Technol.* 2015;4:121.
26. Alshowkan A, et al. Factors affecting the quality of life for people with schizophrenia in Saudi Arabia: A qualitative study. *J Psychiatry.* 2015;18:295.
27. Korenis P, et al. Schizophrenia with somatic delusions: A case report. *J Psychiatry.* 2015;18:290.
28. Naguy A and Al-Mutairi H. Add-on atomoxetine mitigated different symptom domains in a case of early-onset schizophrenia. *J Psychiatry.* 2015;18:279.
29. Kocazeybek B and Kalayci F. Assessment of association between schizophrenia and chlamydiaceae using hill criteria. *J Psychiatry.* 2015;18:250.
30. Zhang J, et al. Interaction between microrna-7 and its target genes in schizophrenia patients. *J psychiatry.* 2015;18:235.
31. Gigi A, et al. Visual impairment affects the perception of reality: Visual processing deficits among adolescents with schizophrenia. *J Psychiatry.* 2015;18:232.
32. Chieffi S, et al. Vulnerability to distraction in schizophrenia. *J Psychiatry.* 2015;18:228.
33. Hukic DS, et al. Genes associated with increased fasting glucose in patients with schizophrenia spectrum disorders. *J Diabetes Metab.* 2015;6:512.
34. Palego L, et al. Sulfur metabolism and sulfur-containing amino acids derivatives – part II: autism spectrum disorders, schizophrenia and fibromyalgia. *Biochem Pharmacol.* 2015;4:159.
35. Werner FM and Covenas R. Clinical efficacy of antipsychotic drugs in the treatment of schizophrenia. *J Cytol Histol.* 2014;S4:013.
36. Singh M, et al. Hypothalamic-pituitary-adrenal (hpa) axis functioning among patients with schizophrenia: A cross sectional comparative study. *J Psychiatry.* 2015;18:211.
37. Bhattacharya K. Cognitive function in schizophrenia: a review. *J Psychiatry.* 2015;18:1000187.
38. Ikemoto K, et al. Lectin-positive spherical deposits (spd) detected in the molecular layer of hippocampal dentate gyrus of dementia, down's syndrome and schizophrenia. *J Alzheimers Dis Parkinsonism.* 2014;4:169.
39. Yavasci EO, et al. Prediction of depression in schizophrenia: Can serum Levels of BDNF or EGF Help us? *J Psychiatry.* 2014;17:1000156.
40. Yang C, et al. A review: Detecting alterations of brain connectivity in schizophrenia based on structural MRI. *J Psychiatry.* 2014;17:159.
41. Jang CH, et al. A case of clozapine-resistant schizophrenia associated with a large arachnoid cyst in the left sylvian fissure. *J Psychiatry.* 2014;17:176.
42. Heinrichs DW, et al. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. *Schizophr Bull.* 1984;10:388-398.
43. Ryan M and Melzer T. Delusions in schizophrenia: Where are we and where do we need to go? *Int J Sch Cog Psychol.* 2014;1:115.

44. Quliti KWA. A case study of partial seizure with secondary generalization induced by clozapine in patient with treatment resistant schizophrenia. *Brain Disord Ther.* 2014;3:145.
45. Millier A, et al. Reasons for aripiprazole discontinuation in schizophrenia – a retrospective. *J Neurol Neurophysiol.* 2014;5:226.
46. Meszaros ZS, et al. Smoking severity and functional MRI results in schizophrenia: A case-series. *J Addict Res Ther.* 2014;5:189.
47. Werner FM. Brain centers involved in schizophrenia. *J Cytol Histol.* 2014;5:e101.
48. Yılmaz ED, et al. Correlation between anxiety and personality in caregivers for patients with schizophrenia. *J Psychiatry.* 2014;17:130.
49. Park AL. Exploring the economic implications of a group-based lifestyle intervention for middle-aged adults with chronic schizophrenia and co-morbid type 2 diabetes. *J Diabetes Metab.* 2014;5:366.
50. Ahmadian S and Zaeifi D. D3 as a possible marker based on d1- d4 dopamine receptors expression in paranoid schizophrenia patients. *J Mol Biomark Diagn.* 2014;5:171.
51. Gharibzadeh S, et al. Reactivation of NMDA receptors by synaptic re-entry reinforcement, a probable cause of auditory hallucination in schizophrenia. *Brain Disord Ther.* 2014;3:118.
52. Rosedale MT, et al. Transcranial direct current stimulation to enhance cognition and functioning in schizophrenia. *J Nov Physiother.* 2014;4:191.
53. Ikemoto K. D-neuron: is it ligand-producing neuron of taar1? From schizophrenia research. *J Community Med Health Educ.* 2013;3:221.
54. Shankar GS and Yuan C. Effects of 5ht2c blockade of dibenzodiazepines on thyroid levels in patients with schizophrenia or schizoaffective disorder. *Autacoids.* 2013;2:102.
55. Jacob A, et al. Abnormal brain circuitry and neurophysiology demonstrated by molecular imaging modalities in schizophrenia. *J Alzheimers Dis Parkinsonism.* 2013;3:114.
56. Khan M and Kabadi UM. Metabolic challenges in schizophrenia. *J Psychol Psychother.* 2013;3:115.
57. Andreica-Sândică B. The necessity of family type interventions during first - episode psychosis in schizophrenia. *J Trauma Treat.* 2012;2:e111.
58. Yamagishi S, et al. Spine homeostasis as a novel therapeutic target for schizophrenia. *Clin Pharmacol Biopharm.* 2012;S1:001.
59. Sandy PT and Mgutshini T. Integrating religiosity into motivational interviewing and nicotine replacement therapy for a patient with schizophrenia and nicotine addiction: Lessons from a mental health service. *J Addict Res Ther.* 2012;3:127.
60. Mas-Expósito L, et al. Physical health and schizophrenia in clinical practice guidelines and consensus statements. *J Addict Res Ther.* 2012;S8:001.
61. Ikemoto K. Are d-neurons and trace amine-associated receptor, type 1 involved in mesolimbic dopamine hyperactivity of schizophrenia? *Med Chem.* 2012;2:038-040.
62. Grover S, et al. Relapse of Tourette syndrome with clozapine in a patient of paranoid schizophrenia. *J Clinic Case Reports.* 2012;2:e112.
63. Tsui MCM. Review of the effects of yoga on people with schizophrenia. *J Yoga Phys Therapy.* 2012;S1:001.
64. Karkhane Yousefi M, et al. A review of varenicline's efficacy and tolerability in smoking cessation studies in subjects with schizophrenia. *J Addict Res Ther.* 2011;S4:001.
65. Zirulnik JL and Pagano MA. Chess-sinthome: A new approach to bobby fischer's psychosis. *Clin Depress.* 2016;2:109.
66. Tonarelli SB, et al. Acceptance and commitment therapy compared to treatment as usual in psychosis: A systematic review and meta-analysis. *J Psychiatry.* 2016;19: 366.
67. Srivastava S, et al. Importance of subtle behavioural changes in the diagnosis of paediatric psychosis. *J Neuropsychopharmacol Mental Health.* 2016;1:108.
68. Tarazi MS, et al. A case of menstruation related psychosis-a rare entity. *Gen Med.* 2016;4:231.
69. Li H, et al. Early psychosis in people from Chinese backgrounds around the world. *J Gen Practice.* 2016;4:249.
70. Mrabet S, et al. IGA nephropathy, β thalassemia minor, psychosis and deafness: A new syndrome? *J Nephrol Ther.* 2016;6:237.
71. McCarthy JB and Libby VG. Limitations of research on psychosis in childhood and adolescence: Current controversies and future directions. *J Ment Disord Treat.* 2016;2:106.

72. Keller R, et al. Diagnostic characteristics of psychosis and autism spectrum disorder in adolescence and adulthood. A case series. *Autism Open Access*. 2016;6:159.
73. Patel R, et al. Improved treatment acceptance and adherence following the diagnosis of multiple malformations of cortical development in a patient with psychosis. *Brain Disord Ther*. 2015;4:192.
74. Farheen SA, et al. Translational science of psychosis in Parkinson's disease. *Clin Depress* 2015;1:102.
75. Ghazali WSW and Rahim MJC. Psychosis secondary to tuberculous meningitis: A case report. *J Clin Case Rep*. 2015;5:581.
76. Gable M and Dwayne Depry DO. Sustained corticosteroid-induced mania and psychosis despite cessation: A case study and brief literature review. *J Clin Case Rep*. 2015;5:546.
77. Wang HY and Chen YC. Escitalopram intoxication induced acute psychosis. *J Clin Toxicol*. 2015;5: 252.
78. Rasheed A, et al. Oral hydrocodone induced acute psychosis in an adult male: A case report. *J Clin Case Rep*. 2015;5:535.
79. Stone MH. Marijuana and psychosis: The effects of adolescent abuse of marijuana and other drugs in a group of forensic psychiatric patients. *J Child Adolesc Behav*. 2015;3:188.
80. de Lacy N and King BH. Revisiting the relationship between autism and schizophrenia: Toward an integrated neurobiology. *Annual review of clinical psychology*. 2013;9:555-587.
81. Chaurasia RN and Mishra V. Hashimoto's encephalopathy presenting as acute psychosis. *Int j neurorehabilitation*. 2014;1:131.
82. Ahmadi J. Improvement of methamphetamine-induced psychosis, retardation and craving after few sessions of ECT. *J Psychiatry*. 2014;17:114.
83. Hommer RE and Swedo SE. Schizophrenia and autism-related disorders. *Schizophrenia Bulletin*. 2015;41:313-14.
84. Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. *J Clin Psychiatry*. 1999;60:52-60.
85. Demitry AE and Mishriky RL. Recognition of postpartum psychosis; obstetricians, gps, midwives, community psychiatric nurses and psychiatrists working together. *Gynecol Obstet (Sunnyvale)*. 2014;4:204.
86. Mukkamalla SKR, et al. Hypertension induced psychosis: a case report. *J Hypertens*. 2014;3:137.
87. Stein NCG, et al. Antibodies to ribosomal p in lupus psychosis resolving after rituximab plus cyclophosphamide – a case report. *J Clin Cell Immunol*. 2013;4:168.
88. Sandyk R. Choroid plexus calcification as a possible marker of hallucinations in schizophrenia. *Int J Neurosci*. 1993;71:87-92.
89. Kumar S, et al. Fahr's disease: a rare neurological disease frequently misdiagnosed as acute psychosis, or mood disorder. *J Neurol Disord*. 2013;1:130.
90. Andreica-Săndică B. The necessity of family type interventions during first - episode psychosis in schizophrenia. *J Trauma Treat*. 2012;2:e111.
91. Sun X, et al. The potential role of melatonin on mental disorders: insights from physiology and pharmacology. *Bipolar Disord*. 2016;2:105.
92. Mouridsen SE, et al. Psychiatric disorders in adults diagnosed as children with atypical autism. A case control study. *Journal of neural transmission*. 2008;115:135-138.
93. Thoma P, et al. Proverb comprehension impairments in schizophrenia are related to executive dysfunction. *Psychiatry Res*. 2009;170:132-139.
94. Castaldo M. Etiology of mental disorders in mothers and children in Mexico. *J Preg Child Health*. 2015;2:206.
95. Wang HG, et al. Genetic and developmental perspective of language abnormality in autism and schizophrenia: one disease occurring at different ages in humans? *Neuroscientist*. 2016;22:119-131.
96. Zaky EA. Second hand smoking and pediatric mental disorders; is there a link? A commentary. *Int Psychol J Sch Cog*. 2015;S1:005.
97. de Oliveira RM, et al. Factors associated with tobacco dependence in people with mental disorders. *J Addict Res Ther*. 2015;6:231.
98. Zaky EA, et al. Association of second hand smoking with mental disorders in children- an Egyptian study. *J Psychol Abnorm Child*. 2015;4:140.
99. Starling J and Dossetor D. Pervasive developmental disorders and psychosis. *Current psychiatry reports*. 2009;11:190-196.
100. Mandal P and Prakash S. Stigma of mental disorders and role of nursing professionals: A developing country perspective. *J Nurs Care*. 2014;3:190.